ORCID as entered in ROS

Select Publications
2024, 'Clinical risk factors associated with development of significant nerve damage during chemotherapy', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 257 - 258
,2024, 'Real world experience with gemcitabine, cisplatin and durvalumab for first line treatment of advanced biliary tract cancers in Australia - Preliminary results', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 197 - 198
,2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023
,2023, 'The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer-Toxicity and interim efficacy data', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023
,2023, 'Inhibition of urokinase plasminogen activator combined with gemcitabine enhances immune regulation and eradicates metastasis in pancreatic cancer', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 31 - 32
,2022, 'CRO-67 is a novel therapeutic for pancreatic cancer: Implications for tumor and stromal reprogramming.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, pp. 161 - 161, presented at AACR Special Conference - Pancreatic Cancer, MA, Boston, 13 September 2022 - 16 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000899825600205&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'ßIII-Tubulin is a brake on extrinsic cell-death in pancreatic cancer.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, pp. 108 - 109, presented at AACR Special Conference - Pancreatic Cancer, MA, Boston, 13 September 2022 - 16 September 2022
,2022, 'LONGITUDINAL TRAJECTORIES OF CLINICAL, NEUROLOGICAL AND PATIENT-REPORTED CHEMOTHERAPY INDUCED PERIPHERAL NEUROTOXICITY FOLLOWING TREATMENT COMPLETION', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, pp. S169 - S169, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000822950200350&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'The psychosocial impact of the Australian Rare Cancer Portal on patients with rare cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022
,2022, 'Two years of the Australian Rare Cancer Portal: a national referral service for rare cancer information and research.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, pp. E18581 - E18581, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022
,2022, 'IMPACT OF PAIN ON SYMPTOM BURDEN IN CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, pp. S86 - S86
,2022, 'Molecular analysis of hepatic epithelioid haemangioendothelioma case series in the Stafford Fox rare cancer program and literature review', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 29 - 30
,2022, 'Patient vignettes reflecting the impact of The Australian Rare Cancer Portal on patients with Rare Cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 182 - 183
,2022, 'The Australian Rare Cancer Portal: Outcomes from the implementation of a national rare cancer platform for referrals and research', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 58 - 59
,2022, 'The first one thousand patients: Demographics of the Australian rare cancer portal 2019-2022', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 35 - 36
,2021, 'A PHASE IB EXPANSION COHORT OF PIXATIMOD PLUS NIVOLUMAB IN PREVIOUSLY TREATED, MICROSATELLITE STABLE METASTATIC COLORECTAL CANCER (MSS MCRC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A367 - A367, http://dx.doi.org/10.1136/jitc-2021-SITC2021.341
,2021, 'A PHASE IB STUDY OF THE SAFETY AND TOLERABILITY OF PIXATIMOD PLUS NIVOLUMAB IN SUBJECTS WITH ADVANCED SOLID TUMORS WITH AN EXPANSION COHORT IN METASTATIC PANCREATIC ADENOCARCINOMA (MPDAC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A366 - A366, http://dx.doi.org/10.1136/jitc-2021-SITC2021.340
,2021, 'Clinical Behavior and Outcome of HPV-Positive Nasopharyngeal Carcinoma', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, pp. E384 - E385
,2021, 'Delivering personalized care and research for rare cancers in the increasingly genomic world?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 92 - 92, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500102&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Effectively communicating comprehensive tumour genomic profiling results: Mitigating uncertainty for advanced cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 180 - 180, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500295&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Psychological outcomes in advanced cancer patients after receiving genomic tumour profiling results', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 198 - 198, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500332&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'The Australian Rare Cancer Portal: A retrospective review of referring oncologist's service requests', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 105 - 106, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500137&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'A psychometric comparison of three approaches to chemotherapy-induced peripheral neuropathy assessment: Patient report, clinical grading, and sensory function', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. S96 - S96, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000712224700205&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'INTEGRATE IIb: A randomised phase III open label study of regorafenib plus nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S1074 - S1074, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1547
,2021, 'Napabucasin plus nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S1084 - S1085, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.794
,2021, 'Multifaceted approach to profiling vincristine-induced peripheral neuropathy', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, pp. 360 - 360, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000696233800123&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Hepatocyte growth factor/c-MET inhibition plus chemotherapy improves tumor immunity and eliminates metastasis in pancreatic cancer', Virtual, presented at Australian Gastroenterology Week, Virtual, 10 August 2021
,2021, 'HEPATOCYTE GROWTH FACTOR/ C-MET PATHWAY INHIBITION COMBINED WITH CHEMOTHERAPY RETARDS PRECURSOR PANINS AND POTENTIATES LOCAL IMMUNITY IN A TRANSGENIC MODEL OF EARLY PANCREATIC CANCER', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, ELECTR NETWORK, pp. S45 - S45, presented at Society-for-Surgery-of-the-Alimentary-Tract Annual Meeting at Digestive Disease Week (DDW), ELECTR NETWORK, 21 May 2021 - 23 May 2021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000649085000104&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Corneal inferior whorl morphology and reproducibility with in-vivo confocal microscopy in peripheral neuropathy', in INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOC RESEARCH VISION OPHTHALMOLOGY INC, ELECTR NETWORK, presented at ARVO Imaging in the Eye Conference, ELECTR NETWORK, 13 May 2021 - 14 May 2021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000720324200022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, '184 HEPATOCYTE GROWTH FACTOR/ C-MET PATHWAY INHIBITION COMBINED WITH CHEMOTHERAPY RETARDS PRECURSOR PANINS AND POTENTIATES LOCAL IMMUNITY IN A TRANSGENIC MODEL OF EARLY PANCREATIC CANCER', in Gastroenterology, Elsevier BV, pp. S - 45, http://dx.doi.org/10.1016/s0016-5085(21)00855-6
,2021, 'Examination of electrochemical skin conductance in chemotherapy-treated patients: Association with neuropathy status', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, pp. 396 - 396
,2021, 'Targeting the urokinase plasminogen activator (uPA) pathway inhibits pancreatic cancer progression', in Pancreatology, Elsevier BV, pp. S73 - S73, http://dx.doi.org/10.1016/j.pan.2021.05.196
,2021, 'Whole exome sequencing across clinical specialties within a medical center', in MOLECULAR GENETICS AND METABOLISM, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. S226 - S227
,2020, 'How much do cancer patients value whole genome sequencing? A cross-sectional survey using the willingness-to-pay technique', in EUROPEAN JOURNAL OF HUMAN GENETICS, SPRINGERNATURE, pp. 790 - 790, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000598482602498&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'The Australian Rare Cancer Portal - A national framework for co-ordinating streamlined access to rare cancer clinical expertise and research', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 206 - 206, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000790145400327&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Pancreatic cancer-related diabetes: Do pancreatic stellate cell and cancer cell derived exosomes play a role?', in Pancreratology, presented at European Pancreatic Club
,2020, 'Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020
,2020, 'Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020
,2020, 'I. Pancreatic Stellate Cell and Cancer Cell Derived Exosomes Impair Beta Cell Function: Implications for Pancreatic Cancer Related Diabetes', in Gastroenterology, Elsevier, Chicago, USA, presented at Digestive Disease Week, Chicago, USA, 02 May 2020, http://dx.doi.org/10.1016/S0016-5085(20)31245-2
,2020, 'The relationship between the Ocular Surface Disease Index and conventional assessments of chemotherapy-induced peripheral neuropathy', in INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOC RESEARCH VISION OPHTHALMOLOGY INC, ELECTR NETWORK, presented at Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO), ELECTR NETWORK, 01 May 2020 - 07 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000554528301316&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'PANCREATIC STELLATE CELL AND CANCER CELL DERIVED EXOSOMES IMPAIR BETA CELL FUNCTION: IMPLICATIONS FOR PANCREATIC CANCER RELATED DIABETES', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, TX, Austin, pp. S221 - S221, presented at Crohn's and Colitis Congress, TX, Austin, 23 January 2020 - 25 January 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000540349500565&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, CA, San Francisco, 23 January 2020 - 25 January 2020
,2020, 'Characterization of circulating pancreatic stellate cells in pancreatic cancer by single-cell transcriptomic analysis', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 161 - 162
,2020, 'Inhibition of both the ligand and receptor of the hepatocyte growth factor/c-MET pathway, in combination with chemotherapy, retards progression of PanIN lesions in KPC mice', in Pancreatology, Elsevier BV, pp. S39 - S40, http://dx.doi.org/10.1016/j.pan.2020.07.049
,2020, 'Psychological impact of comprehensive genomic profiling results to advanced cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 92 - 92
,2019, 'A Novel Adjuvant Treatment Approach in Pancreatic Cancer Via Hepatocyte Growth Factor (HGF)/c-MET Inhibition', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, pp. 1504 - 1504, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000505712800433&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'hENT1 RNA and Protein in Combination May Act as Predictive Biomarkers for Survival for Patients Treated With Adjuvant Gemcitabine in Pancreatic Cancer', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, pp. 1436 - 1437, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000505712800168&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'How can digital health be used to improve outcomes in pancreatic ductal adenocarcinoma (PDAC)? Examining the potential of the PURPLE translational pancreatic cancer platform', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 73 - 74, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Inhibition of Hepatocyte Growth Factor (HGF) Signaling Pathway in Combination With Chemotherapy Reduces Tumour Burden in an Orthotopic Model of Advanced Pancreatic Cancer', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, pp. 1551 - 1551, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000505712800617&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'International volunteering through ASCO - a Vietnam experience', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 69 - 69, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,